JZUS - Journal of Zhejiang University SCIENCE

Journal of Zhejiang University SCIENCE B 2005 Vol.6 No.7 P.656-663

http://doi.org/10.1631/jzus.2005.B0656

Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34^cdc2 kinase

Author(s): YANG Hua, ZHENG Shu, MEIJER Laurent, LI Shi-min, LECLERC Sophie, YU Lin-lin, CHENG Jin-quan, ZHANG Su-zhan
Affiliation(s): Cancer Institute, Zhejiang University, Hangzhou 310009, China; more
Corresponding email(s): YangH@moffitt.usf.edu, zhengshu@zju.edu.cn
Key Words: Chinese medicinal herbs, Cdc25 phosphatase inhibition, Cell cycle, Anti-tumor activity

Share this article to： More <<< Previous Article \|Next Article >>>

Abstract: Objective: To screen and evaluate the active constituents of chinese medicinal herbs as potent inhibitors of Cdc25 phosphatase. Methods: The affinity chromatography purified glutashione-S-transferase/Cdc25A phosphatase fusion protein and Cdc2/cyclin B from the extracts of starfish M phase oocytes are used as the cell cycle-specific targets for screening the antimitotic constituents. We tested 9 extracts isolated from the chinese medicinal herbs and vegetables including the agents currently used in cancer treatment by measuring the inhibition of Cdc25A phosphatase and Cdc2 kinase activity. The antitumor activity of the extracts was also evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and flow cytometry. Results: Cdc25A inhibitory activity and antitumor activity are detected in the extracts isolated from three chinese medicinal herbs Agrimona pilosa; Herba solani lyrati; Galla chinesis. Conclusion: We found three extracts isolated from chinese medicinal herbs have potential inhibitory activity of Cdc25 phosphatase using a highly specific mechanism-based screen assay for antimitotic drug discovery.

Reference

[1] Baratte, B., Meijer, L., Galaktionov, K., Beach, D., 1992. Screening for antimitotic compounds using the Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein kinase. Anticancer Res., 12:873-880.

[2] Cangi, M.G., Cukor, B., Soung, P., Signoretti, S., Moreira, J., Ranashinge, G.M., Cady, B., Pagano, M., Loda, M., 2000. Role of Cdc25A phosphatase in human breast cancer. J Clin Invest, 106:753-761.

[3] Choudhary, B., 2002. The new international seed treaty: Promises and prospects for food security. Current Science, 83:366-369.

[4] Constantinou, A., Stoner, G.D., Mehta, R., Rao, K., Runyan, C., Moon, R., 1995. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro. Nutr Cancer., 23:121-130.

[5] Farnsworth, N.R., Loub, W.D., 1983. Information Gathering and Data Hases that are Pertinent to the Development of Plant-derived Drugs. In: The Potentials for Extracting Protein, Medicines, and Other Useful Chemicals. Workshop Proceedings, OTA-BP-F-23. US Congress, Office of Technology Assessment, Washington, D.C., p.178-195.

[6] Farnsworth, N.R., Soejarto, D.D., 1985. Potential consequences of plant extinction in the United States on the current and future availability of prescription drugs. Econ. Bot., 39:231-240.

[7] Farnsworth, N.R., Akerele, O., Bingel, A.S., Soejarto, D.D., Guo, Z., 1985. Medicinal plants in therapy. Bull. WHO, 63(6):965-981.

[8] Galaktionov, K., Lee, A.K., Eckstein, J., Draetta, G., Meckler, J., Loda, M., Beach, D., 1995. Cdc25 phosphatases as potential human oncogenes. Science (Wash DC), 269:1575-1577.

[9] Galaktionov, K., Chen, X., Beach, D., 1996. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature (Lond), 382:511-517.

[10] Ham, S.W., Park, J., Lee, S.J., Kim, W., Kang, K., Choi, K.H., 1998. Naphthoquinone analogs as inactivators of Cdc25 phosphatase. Bioorg Med Chem Lett, 8:2507-2510.

[11] Hernandez, S., Bessa, X., Bea, S., Hernandez, L., Nadal, A., Mallofre, C., Muntane, J., Castells, A., Fernandez, P.L., Cardesa, A., 2001. Differential expression of Cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab Invest, 81:465-473.

[12] Hoffman, I., Draetta, I., Karsenti, G., 1994. Activation of the phosphatase activity of human Cdc25A by a CDK2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J, 13:4302-4310.

[13] Hotz, M.A., Gong, J., Traganos, F., Darzynkiewicz, Z., 1994. Flow cytometric detection of apoptosis: Comparison of the assays of in situ DNA degradation and chromatin changes. Cytometry, 5:237-241.

[14] Jinno, S., Suto, J., Nagata, A., Igarashi, M., Kanaoka, Y., Nojima, H., Okayama, H., 1994. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J, 13:1549-1556.

[15] Kim, H.J., Kang, S.K., Mun, J.Y., Chun, Y.J., Choi, K.H., Kim, M.Y., 2003. Involvement of Akt in mitochondria-dependent apoptosis induced by a Cdc25 phosphatase inhibitor naphthoquinone analog. FEBS Lett., 555:217-222.

[16] Lazo, J.S., Aslan, D.C., Southwick, E.C., Cooley, K.A., Ducruet, A.P., Joo, B., Vogt, A., Wipf, P., 2001. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem, 44:4042-4049.

[17] Lazo, J.S., Nemoto, K., Pestell, K.E., 2002. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol, 61:720-728.

[18] Losso, J.N., Bansode, R.R., Trappey, A., Bawadi, H.A., Truax, R., 2004. In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem., 15:672-678.

[19] Loukaci, A., Le Saout, I., Samadi, M., Leclerc, S., Damiens, E., Meijer, L., Debitus, C., Guyot, M., 2001. Coscinosulfate, a Cdc25 phosphatase inhibitor from the sponge coscinoderma mathewsi. Bioorg Med Chem., 9:3049-3054.

[20] Lyon, M.A., Ducruet, A.P., Wipf, P., Lazo, J.S., 2002. Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov, 1:961-976.

[21] Mailand, N., Falck, J., Lukas, C., Syljuasen, R.G., Welcker, M., Lukas, J., 2000. Rapid destruction of human Cdc25A in response to DNA damage. Science (Wash DC), 288:1425-1429.

[22] Mertens-Talcott, S.U., Percival, S.S., 2005. Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. Cancer Lett., 218:141-151.

[23] Millar, J.B., Blevitt, J., Gerace, L., Sadhu, K., Featherstone, C., Russell, P., 1991. p55Cdc25 is a nuclear protein required for the initiation of mitosis in human cells. Proc Natl Acad Sci USA, 88:10500-10504.

[24] Molinari, M., Mercurio, C., Dominguez, J., Goubin, F., Draetta, G.F., 2000. Human Cdc25A inactivation is response to S phase inhibition and its role in preventing premature mitosis. EMBO J., 1:71-79.

[25] Mukherjee, P.K., 2003. GMP for Indian Systems of Medicine. In: Mukherjee, P.K., Verpoorte, R. (Eds.), GMP for Botanicals: Regulatory and Quality Issues on Phytomedicines. Business Horizons, New Delhi, p.99-112.

[26] Nagata, A., Igarashi, M., Jinno, S., Suto, K., Okayama, H., 1991. An additional homolog of the fission yeast Cdc25+ gene occurs in humans and is highly expressed in some cancer cells. New Biologist, 3:959-968.

[27] Nilsson, I., Hoffman, I., 2000. Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res, 4:107-114.

[28] Prevost, G.P., Brezak, M.C., Goubin, F., Mondesert, O., Galcera, M.O., Quaranta, M., Alb, Y.F., Lavergne, O., Ducommun, B., 2003. Inhibitors of the Cdc25 phosphatases. Prog Cell Cycle Res., 5:225-234.

[29] Pu, L., Amoscato, A.A., Bier, M.E., Lazo, J.S., 2002. Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino)-quinoline-5,8-dione. J Biol Chem, 277:46877-46885.

[30] Ramakrishnappa, K., 2003. Impact of Cultivation and Gathering of Medicinal Plants on Biodiversity: Case Studies from India. Biodiversity and the Ecosystem Approach in Agriculture, Forestry and Fisheries. United Nations Publications, New York, USA, p.210-215.

[31] Sadhu, K.S., Reed, I., Richardso, N.H., Russell, P., 1990. Human homolog of fission yeast Cdc25 mitotic inducer is predominantly expressed in G₂. Proc Natl Acad Sci USA, 87:5139-5143.

[32] Sohn, J., Kiburz, B., Li, Z., Deng, L., Safi, A., Pirrung, M.C., Rudolph, J., 2003. Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones. J Med Chem., 46:2580-2588.

[33] Tamura, K., Southwick, E.C., Kerns, J., Rosi, K., Carr, B.I., Wilcox, C., Lazo, J.S., 2000. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res, 60:1317-1325.

[34] Twentyman, P.R., Fox, N.E., Rees, J.K., 1989. Chemosensitivity testing of fresh leukemia cells using the MTT colorimetric assay. Br J Haematol, 71:19-22.

[35] Wakdikar, S., 2004. Global health care challenge: Indian experiences and new prescriptions. Electronic J of Biotechnology, 7:214-220.

[36] Yang, H., Wang, X.P., Yu, L.L., Zheng, S., 1996. The antitumor activity of elemene is associated with apoptosis. Zhonghua Zhong Liu Za Zhi., 18:169-172 (in Chinese).

[37] Zheng, S., Yang, H., Zhang, S., Wang, X., Yu, L., Lu, J., Li, J., 1997. Initial study on naturally occurring products from traditional Chinese herbs and vegetables for chemoprevention. J Cell Biochem, 27(Suppl):106-112.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Similar articles

- Go to

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference